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ABSTRACT
Objective: Etoposide is a potent anticancer drug and a major limiting factor that hinders therapeutic use as its high levels of systemic circulation 
often associated with various off-target effects, particularly cardiotoxicity. The present study focuses on the evaluation of the anticancer activity of 
optimized etoposide nanoparticles compared with marketed etoposide formulation in experimental animal models.
Methods: Albino rats (180–200 g) were used for the study. The anticancer effect of the formulated etoposide nanoparticles was evaluated by induction 
of hepatocellular carcinoma (HCC). The animals housed in cages and kept on a 12 h light/dark cycle. Following the acclimatization for 1 week, HCC 
will be induced in rats by adding 100 mg/L of diethylnitrosamine (DENA) in drinking water for 8 weeks. Drug treatment (etoposide [9 mg/kg] in 
0.5 % carboxymethyl cellulose; p.o.) can be started at the end of 1 week after cancer induction and dose of 9 mg/kg of etoposide and lyophilized 
nanoparticles will be administered through oral route on 1, 7, 14, 21, and 28 days. Nanoformulations were evaluated in healthy rats, and anticancer 
activity was studied in DENA treated rats.
Results: The results showed that the polymeric nanoparticles containing etoposide was screened for its anticancer activity by counting the liver 
nodules of rats with hematoxylin and eosin stain when comparing control and etoposide-treated group.
Conclusion: The results of the study concluded that in rats treated with nanoformulations, the numbers of liver nodules were found to be significantly 
reduced.
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INTRODUCTION
Cancer is a major public health problem in the world. There were 
14.1 million new cancer cases and 8.2 million cancer deaths in 2012 
worldwide. If these rates do not change, the global cancer burden is 
expected to nearly double to 21.4 million cases and 13.5 million deaths 
by 2030. Whereas the breast cancer is the most common cancer among 
women population in worldwide, with nearly 1.7 million new cases 
diagnosed in 2012 (the second most common cancer). This survey 
represents about 12% of all new cancer cases and 25% of all cancers in 
women. Cancer is the second leading cause of death worldwide and was 
responsible for 8.8 million deaths in 2015. As per the WHO, nearly 1 in 
6 deaths is due to cancer.
A typical example of topoisomerase inhibitors is etoposide, and it is the 
first line of chemotherapeutic agents that are used in the treatment of 
many types of cancer. The mechanism of action of etoposide by forming 
a ternary complex with topoisomerase II and DNA, causing DNA breaks, 
and cell death [1]. In addition to this, there are many side effects 
related to the drug [2-4], the administration of etoposide is rate limited 
by its low solubility in aqueous solutions [5,6]. Therefore, finding an 
effective approach to facilitate the transport of drugs and to improve 
the bioavailability of therapeutics is necessary.
The drug candidate etoposide has variable oral bioavailability and 
ranging from 24% to 74% and has terminal half-life of 1.5 h by 
intravenous route and 0.44 h by the oral route. The conventional oral 
therapy has the drawback of low bioavailability, and parenteral therapy 
causes inconvenience and pain to the patients as it has to be given 
through a continuous IV infusion over 24–34 h. Hence, the objective 
of the present study was made for anticancer activity of etoposide 
polymeric nanoparticles in comparison with pure and marketed 
formulation using albino rats as an animal model.
MATERIALS AND METHODS
Materials
Etoposide was a gift sample from Biocon Limited, Bengaluru, India; 
Eudragit® EPO and HPMC K-15 were gifts from Cipla Pharmaceuticals, 
Mumbai, India. Pluronic® F-68 gifted from Alembic Pharmaceuticals, 
Mumbai, India. High-performance liquid chromatography grade of 
methanol, water, and acetonitrile was purchased from Qualigens fine 
chemicals Mumbai, India. All other reagents and chemicals used in this 
study were of analytical grade.
Preparation of Eudragit EPO based nanoparticle suspension
Nanoparticles suspensions were prepared by nanoprecipitation 
method. Dissolved the drug (50 mg) and specific amount of Eudragit®-
EPO (0.45%) in 15 ml of methanol. The organic solution quickly 
injected to 40 ml aqueous solution containing Pluronic® F-68 under 
stirring at 2000 rpm. Stirring was continued for 2 h at 40°C for complete 
evaporation of methanol. The volume was adjusted up to 40 ml with 
an aqueous solution of 200 mg of HPMC K-15 to obtain a nanoparticle 
suspension. The optimized nanoparticles suspension was lyophilized 
at −42°C for 72 h and which also redispersed in water to get aqueous 
nanoparticles suspension [7].
In previous work, 32 factorial designs were used to optimize the process 
parameters such as polymer concentration and stabilizer concentration. 
Two dependent variable’s drug content, entrapment efficiency was 
measured as responses. Mathematical equations and response 
surface plots were used to relate the dependent and independent 
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variables. The particle size of optimised formulation was found to be 
131.4±0.057 nm, entrapment efficiency of about 94.28±0.198% and 
drug content of 88.36±0.075%. The observed responses were in close 
agreement with the predicted values of the optimized process. The 
prepared nanoparticle was characterized by Fourier transform infrared 
spectroscopy, X-ray diffraction, and morphological studies, in vitro drug 
release studies, kinetic modeling, and stability studies. The prepared 
nanoparticle was showed good sustained release of drug up to 24 h [8]. 
Based on in vitro parameters, the optimized subjected to anticancer 
activity studies and its comparison with the marketed formulation.
Evaluation of anticancer activity
Experimental animals
Animals (albino rats) were allowed standard pellet food and water 
ad libitum.
Animals housed in colony cages under standard laboratory conditions 
(12:12 h light and dark cycles, temperature maintained at 25±2°C, and 
relative humidity 55±10%). Animals were allowed to acclimate for 
7 days to the laboratory conditions before the conduct of experiments. 
An experimental protocol approved by the Institutional Animal Ethical 
Committee (APCP/IAEC/409/01) before starting the research work. 
Experiments were performed in accordance with the current guidelines 
of CPCSEA.
Based on the results of in vitro studies, the optimized nanoparticles 
were chosen for this study. The anticancer activity was assessed using 
albino rats.
Induction of hepatocellular carcinoma (HCC)
Male rats (weight: 180–200 g) will be housed in cages and kept on a 
12 h light/dark cycle. Following the acclimatization for 1 week, HCC will 
be induced in rats by adding 100 mg/l of diethylnitrosamine (DENA) in 
drinking water for 8 weeks [9-11].
Treatment
Anticancer experiments will be carried out using 6 rats (cancer-induced 
as above) in each group. The rats will be divided into three groups and 
maintained for 1 week.
Group I - Control to receive only 0.5% w/v sodium carboxymethyl 
cellulose (CMC); p.o.
Group II - To receive etoposide (9 mg/kg) in 0.5% CMC; p.o.
Group III - To receive optimized nanoparticles containing equivalent 
amount of etoposide (9 mg/kg) in 0.5% CMC; p.o.
Drug treatment can be started at the end of 1 week after cancer induction, 
and dose of 9 mg/kg of etoposide and lyophilized nanoparticles will be 
administered through oral route on 1, 7, 14, 21, and 28 days.
Analysis
During treatment, weight of animals will be monitored. Following 
treatment completion on day 28, the animals will be sacrificed under 
anesthetic ether. The liver can be removed, and lobes will be separated. 
Tumor nodules on the surface of each lobe measuring 3 mm in diameter 
(measured with a digital caliper) will be counted, and the difference 
in the number of nodules in the three experimental groups is needed 
to be statistically evaluated. A second evaluation of tumor growth will 
be performed after the lobes are fixed in 10% formalin, which makes 
neoplastic nodules more evident. The upper and lower surfaces of each 
fixed lobe, together with a millimeter graded bar will be photographed 
for the digital enlargements of the photos. Since lumps smaller than 
2 mm could not be identified with much certainty as nodules, this is 
not counted. In livers displaying a multi-nodular surface, identifiable 
nodules will be counted to a maximum of 50, since the total number 
could not be reliably assessed. The antitumor effect of the drugs and 
nanoparticles was estimated by comparing the number of animals 
with more than 50 tumor masses in each of the different experimental 
groups. Samples of all the lobes of the liver will be fixed in 10% formalin 
embedded in paraffin and were routinely stained with hematoxylin and 
eosin (H and E).
Statistical analysis
Results are expressed as a mean±standard error of the mean (n=6). The 
statistical analysis of data was done using one-way analysis of variance, 
followed by Dunnett’s t-test. Probability level <0.05 was considered 
statistically significant.
RESULTS AND DISCUSSION
Histological analysis of treated rats
Hepatic cellular carcinoma is induced by oral administration of DENA. 
The results of the study showed the significant formation of HCC as 
evidenced by the formation of nodules on liver tissue and also from the 
cancerous cellular growth profile in liver histochemical sections (Fig. 1). 
When the rats were treated with etoposide, the nodule formation was 
found relatively reduced with some cancerous growth still evident in 
liver sections (Fig. 1). The rats who were treated with etoposide showed 
that the many numbers of the nodules have disappeared and suggesting 
the maximum inhibition of HCC, which is further confirmed by 
histochemical analysis of liver tissue sections showed with the control 
group. These observations suggest that the polymeric nanoparticle 
formulations of etoposide are highly efficacious compared to etoposide. 
Mean body weight (MBW) was measured for each group animals. DENA 
induced HCC rat shows an increase in MBW was found to be 204.66 g ± 
0.816. When treated with etoposide, its MBW is decreased significantly 
indicating the severe toxic effects exerted by the drug (193.83 g ± 1.169, 
while in the case of treatment with etoposide MBW of animals was 
found significantly restored (180.33 g ± 0.516) with a slight decrease 
in weight due to inhibition of cancer growth. Thus, nanoparticle 
encapsulation of etoposide has reduced the etoposide-related weight 
loss establishing its reduced off-target effects when delivered with 
polymeric nanoparticles.
Fig. 1 shows the treatment of HCC. HCC was induced by adding 
100 mg/L of DENA in drinking water for 8 weeks. After 1 week of 
the gap from the DENA treatment, animals received 9 mg/g of drug 
equivalent of Etoposide through oral administration on 1, 7, 14, 21, 
and 28 days. Panel A shows untreated liver with a maximum number 
of nodules which were reduced to some extent when treated with 
Etoposide (panel B). HCC was significantly reduced when treated with 
etoposide nanoparticles (Panel C), which is indicated by the reduction 
in the number of nodules. It is further analyzed by H and E analysis of 
liver nodules along with treatments.
CONCLUSIONS
The present investigation concludes that the anticancer activity 
of etoposide polymeric nanoparticles was found to be statistically 
significant in comparison with pure and marketed formulation using 
albino rats as an animal model.
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          A. Control                                               B. Etoposide                               C. Polymeric nanoparticles 
Fig. 1: Anticancer activity (Panel A) shows untreated liver with maximum number of nodules which were reduced to some extent when 
treated with etoposide (panel B). HCC was significantly reduced when treated with etoposide nanoparticles (Panel C), which is indicated 
by the reduction in the number of nodules. It is further analyzed by hematoxylin and eosin analysis of liver nodules along with treatments
